Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.57 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.57 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | TARS1 | P26639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146527 | 0.92 | TLR8 (0.61) | TLR8TLR7LIMK1LOXL2CTSS | |
| SCHEMBL3988438 | 0.85 | TLR8 (0.54) | TLR8TLR7LIMK1DHFR | |
| SCHEMBL5146429 | 0.82 | TLR8 (0.61) | TLR8TLR7 | |
| SCHEMBL3981001 | 0.82 | TLR8 (0.60) | TLR8TLR7LIMK1 | |
| SCHEMBL3503556 | 0.81 | TLR8 (0.56) | TLR8TLR7DHFR | |
| SCHEMBL3980452 | 0.81 | TLR8 (0.61) | TLR8TLR7LIMK1DHFR | |
| SCHEMBL5144714 | 0.80 | TLR8 (0.54) | TLR8TLR7LIMK1DHFR | |
| SCHEMBL5144935 | 0.79 | TLR8 (0.53) | TLR8TLR7DHFR | |
| SCHEMBL3503555 | 0.78 | TLR8 (0.57) | TLR8TLR7DHFR | |
| SCHEMBL5144711 | 0.78 | TLR8 (0.58) | TLR8TLR7DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-11-08 | — | — | US | disclosed |
| WO-2006093514-A2 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259907-A1 | ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, TSLP, IFNG | TLR8 86/4885TLR7 39/4885LIMK1 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.